AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Entropy Neurodynamics Limited

0.039

+0.0024.00%

Volume:2.66M

Turnover:101.44K

Market Cap:63.61M

PE:-12.56

High:0.039

Open:0.038

Low:0.038

Close:0.038

52wk High:0.046

52wk Low:0.025

Shares:1.63B

Float Shares:878.05M

Volume Ratio:1.85

T/O Rate:0.30%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.003

EPS(LYR):-0.004

ROE:-92.06%

ROA:-45.59%

PB:8.00

PE(LYR):-10.00

Loading ...

Overview Company News Filings

Entropy Neurodynamics - Trading Halt Pending Announcement on Binge Eating Disorder Study Data

THOMSON REUTERS

Entropy Neurodynamics Completes First-Cohort Dosing in Binge Eating Disorder Trial

MT Newswires Live

Entropy Neurodynamics Says Various Securities Due for Escrow Release; Shares Up 3%

MT Newswires Live

Entropy Neurodynamics Says Irritable Bowel Syndrome Drug Candidate Showed 75% Response Rate in Phase 2a Study; Shares Gain 3%

MT Newswires Live

Entropy Neurodynamics Completes Recruitment of First Group in Binge Eating Disorder Trial; Shares Rise 3%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/ENP.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ENP.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ENP.AU\",,,,,undefined,":{"symbol":"ENP.AU","market":"AU","secType":"STK","nameCN":"Entropy Neurodynamics Limited","latestPrice":0.039,"timestamp":1787292720000,"preClose":0.0375,"halted":0,"volume":2656197,"delay":0,"changeRate":0.040000000000000036,"nameEN":"Entropy Neurodynamics Limited","floatShares":878046607,"shares":1631064683,"eps":-0.003104,"marketStatus":"Not Yet Opened","change":0.0015,"latestTime":"08-21 16:12:00 AEST","open":0.038,"high":0.039,"low":0.038,"amount":101437,"amplitude":0.026667,"askPrice":0.04,"askSize":1408817,"bidPrice":0.038,"bidSize":157894,"shortable":3,"etf":0,"ttmEps":-0.003104,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.0375,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":1.851010168336109,"lotSize":0,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ENP.AU","preClose":0.0375,"auctionPrice":0.039,"auctionVolume":25000,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292481595}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ENP.AU\",,,,,undefined,":{"symbol":"ENP.AU","floatShares":878046607,"roa":"-45.59%","roe":"-92.06%","lyrEps":-0.0039,"volumeRatio":1.851010168336109,"shares":1631064683,"dividePrice":0,"high":0.039,"amplitude":0.026667,"preClose":0.0375,"low":0.038,"week52Low":0.025,"pbRate":"8.00","psRate":"40.22","week52High":0.046,"institutionHeld":0,"latestPrice":0.039,"committee":-0.798439,"eps":-0.003104,"divideRate":0,"volume":2656197,"delay":0,"ttmEps":-0.003104,"open":0.038,"prevYearClose":0.033,"prevWeekClose":0.036,"prevMonthClose":0.035,"prevQuarterClose":0.032,"fiveDayClose":0.036,"twentyDayClose":0.037,"sixtyDayClose":0.031},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENP.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENP.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENP.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2648639174","title":"Entropy Neurodynamics - Trading Halt Pending Announcement on Binge Eating Disorder Study Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2648639174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648639174?lang=en_us&edition=fundamental","pubTime":"2026-07-03 07:09","pubTimestamp":1783033780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nFWN4340JE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ENP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640995148","title":"Entropy Neurodynamics Completes First-Cohort Dosing in Binge Eating Disorder Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640995148","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640995148?lang=en_us&edition=fundamental","pubTime":"2026-06-02 09:23","pubTimestamp":1780363439,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics (ASX:ENP) said it completed dosing for all six participants in the first cohort of its phase two clinical trial of TRP-8803 for the treatment of patients with binge eating disord","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637367427","title":"Entropy Neurodynamics Says Various Securities Due for Escrow Release; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637367427","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637367427?lang=en_us&edition=fundamental","pubTime":"2026-05-22 12:11","pubTimestamp":1779423086,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics  said a range of its restricted securities will be released from escrow on May 29, following which it will not have any securities remaining in escrow, according to a Friday filing with the Australian bourse.The securities to be released include about 49.9 million ordinary shares, as well as various options, per the filing.The company said it will apply to quote the ordinary shares within five business days after the end of the escrow period.Shares of Entropy Neurodynamics gained nearly 3% in recent Friday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632749980","title":"Entropy Neurodynamics Says Irritable Bowel Syndrome Drug Candidate Showed 75% Response Rate in Phase 2a Study; Shares Gain 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632749980","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632749980?lang=en_us&edition=fundamental","pubTime":"2026-05-04 13:03","pubTimestamp":1777871026,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics (ASX:ENP) said its TRP-8802 drug candidate showed a 75% response rate in a phase 2a clinical study for the treatment of irritable bowel syndrome, according to a Monday filing wit","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","ENP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616957398","title":"Entropy Neurodynamics Completes Recruitment of First Group in Binge Eating Disorder Trial; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616957398","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616957398?lang=en_us&edition=fundamental","pubTime":"2026-03-03 08:28","pubTimestamp":1772497695,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics  said recruitment for the first group in its clinical trial of its TRP-8803 drug candidate, or intravenous-infused psilocin, in the treatment of binge eating disorder was completed, with six patients enrolled, according to a Tuesday Australian bourse filing.The study's primary endpoint is safety and tolerability of two administrations of TRP-8803 over 12 weeks following first dosing. The secondary and exploratory endpoints include the assessment of changes in binge eating frequency, body mass index, weight-related measures, and broader psychological parameters.It will recruit a total of 12 patients with binge eating disorder, in two six-person groups. Each group will receive two doses of TRP-8803, 14 days apart, in conjunction with supportive therapy. The first group will receive a mid-range therapeutic dose.The first and second patients in the first group completed both dosing sessions. The third, fourth, and fifth patients completed their four-week baseline asse","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":25,"code":"91000000","status":"200"}]}}